cgp 12177 has been researched along with Coronary Disease in 1 studies
CGP 12177 : A benzimidazole that is benzimidazol-2-one substituted at position 4 by a 3-(tert-butylamino)-2-hydroxypropoxy group.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Watson-Wright, WM | 1 |
| Armour, JA | 1 |
| Johnstone, DE | 1 |
| Wilkinson, M | 1 |
1 other study available for cgp 12177 and Coronary Disease
| Article | Year |
|---|---|
Myocardial slice: a physiological approach to beta-adrenergic ([3H] CGP-12177) receptor binding in hamster and guinea pig heart.
Topics: Adrenergic beta-Antagonists; Animals; Coronary Disease; Cricetinae; Freezing; Heart; In Vitro Techni | 1989 |